- Fourth quarter in a row with growth
1 Januay-31 March
- Net sales reached
SEK 5,6 (4,6) million - Loss after taxes
SEK -3,2 (-2,1) million - Earnings per share were
SEK -0,06 SEK (-0,04) - Cash and equivalents were 6,3 (7,9) million
Significant events during period
- CE-mark for the new platform Eagle obtained
- Patent that include the Schelin Catheter is approved
- An agreement with a new clinic in
Stockholm was signed - An agreement with a new clinic in Karlshamn was signed
- Agreement with SLG Kalmar is signed with an order value of
SEK 2,4 million
Significant events after the end of the period
- Distribution agreement for
Poland was signed - Schelin Catheter® approved for sale in the province of
Hainan inChina - The board decided on
May 17th 2023 to carry out a rights issue of approx. 40 MSEK before issue costs
Key figures | ||||
( | jan-mar 2023 | jan-mar 2022 | jan-mar 2021 | jan-mar 2020 |
Net sales | 5,6 | 4,6 | 5,3 | 4,6 |
Gross margin, % | 68 | 81 | 83 | 72 |
Operating profit/loss | -3,2 | -2,1 | -1,2 | -1,6 |
Cash flow from operating activities | -5,5 | -5,1 | -2,2 | 1,4 |
Average number of employees | 9 | 7 | 7 | 5 |
”The first quarter of the year was characterized by the same intensity as 2022. We began the year with continued growth and reported the highest turnover ever during a quarter”
CEO,
Please see attached PDF for full report.
© Modular Finance, source